Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BOS complex subunit NOMO3 (NOMO3) is a widely conserved type I transmembrane glycoprotein that is a component of the multi-pass translocon (MPT) complex, mediating the insertion of multi-pass membrane proteins into the lipid bilayer of membranes after initial steps by the SEC61 complex. NOMO3, in conjunction with its paralogs NOMO1 and NOMO2, plays a role in the maintenance of ER morphology, specifically in imposing and regulating the spacing of ER sheets and potentially affecting autophagic and lysosomal routes. While NOMO family proteins have been implicated in the regulation of Nodal signaling during vertebrate development, direct disease associations remain limited or are attributed to nearby genes. No known drugs or therapeutic targeting have been described for this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BOS complex subunit NOMO3 (NOMO3).